Home › Glioblastoma › Michigan › Ann Arbor
Glioblastoma clinical trials in Ann Arbor, MI
6 studies for Glioblastoma are looking for participants at sites in and around Ann Arbor (within about 30 miles). Open a study to see who can join and how to contact the study team.
Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
- C.S. Mott Children's Hospital, Ann Arbor
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
RecruitingPhase 2
- University of Michigan Rogel Cancer Center, Ann Arbor
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
RecruitingPhase 1
- University of Michigan, Ann Arbor
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RecruitingPhase 2
- C.S. Mott Children's Hospital, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Ann Arbor
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RecruitingPhase 1/2
- University of Michigan, Ann Arbor
Glioblastoma trials in other cities
- New York City, NY30 studies
- Boston, MA29 studies
- Houston, TX25 studies
- Los Angeles, CA22 studies
- Durham, NC20 studies
- San Francisco, CA18 studies
- Chicago, IL16 studies
- Washington, DC15 studies
- Rochester, MN15 studies
- Columbus, OH14 studies
- Miami, FL14 studies
- Jacksonville, FL13 studies
Other studies in Ann Arbor
- Prostate Cancer27 studies
- Breast Cancer26 studies
- Cancer (all types)26 studies
- Non-Small Cell Lung Cancer25 studies
- Colorectal Cancer23 studies
- Heart Failure22 studies
- Lung Cancer22 studies
- Acute Myeloid Leukemia17 studies
- Cardiovascular Disease16 studies
- Pancreatic Cancer14 studies
- Melanoma12 studies
- Kidney Cancer (Renal Cell Carcinoma)12 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.